Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Emergency Guide: When to see the doctorIt is very important that every person o...
-
Kim Smith-Whitley, MDDr. Smith-Whitley is the director of the...
-
IU Nurse Invents Medical Device for People With Sickle Cell Diseasehttps://www.youtube.com/watch?v=TjE3Urth...
-
Our healthcare system abandons adult sickle cell patientsWhen Janoi Burgess was a child, he thoug...
-
Alexis Thompson, MD, MPHDr. Alexis Thompson is currently the Hem...
-
Flying doctor takes to the skies after sister’s deathOlamide Orekunrin was studying to become...
-
MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-m...Hematopoietic stem cell transplant for s...
